Market Insights Health Hospitals Inpatient Care

Treatment of Musculoskeletal Diseases - EU-27

EU-27

In the EU-27, the projected revenue for the Treatment of Musculoskeletal Diseases market in 2024 is estimated to be US$33.15bn.
It is expected that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 2.17%, leading to a market volume of US$36.91bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$60,790.00m in 2024.
In the EU-27, Germany's strong healthcare system and focus on research and innovation make it a leader in the treatment of musculoskeletal diseases.

Key regions: Europe, Canada, United States, Germany, India

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.